サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1758767

濾胞性甲状腺がん治療薬の世界市場

Follicular Thyroid Cancer Drugs

出版日
ページ情報
英文 278 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.09円
濾胞性甲状腺がん治療薬の世界市場
出版日: 2025年06月30日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 278 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

濾胞性甲状腺がん治療薬の世界市場は2030年までに9億850万米ドルに達する見込み

2024年に7億1,530万米ドルと推定される濾胞性甲状腺がん治療薬の世界市場は、2024～2030年の分析期間に4.1％のCAGRで成長し、2030年には9億850万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである乳頭がんタイプは、CAGR 3.9%を記録し、分析期間終了時には5億1,550万米ドルに達すると予測されます。濾胞がんタイプの成長率は、分析期間中CAGR 4.6%と推定されます。

米国市場は1億9,490万米ドルと推定、中国はCAGR7.4％で成長すると予測

米国の濾胞性甲状腺がん治療薬市場は、2024年に1億9,490万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを7.4%として、2030年までに1億8,460万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.7%と3.2%と予測されています。欧州では、ドイツがCAGR 2.4%で成長すると予測されています。

世界の濾胞性甲状腺がん治療薬市場- 主要動向と促進要因のまとめ

濾胞性甲状腺がんの治療情勢はなぜ急速に進化しているのか？

甲状腺濾胞がん（FTC）は、甲状腺乳頭がんに次いで2番目に多い分化型甲状腺がんであり、治療上のユニークな課題と機会を提供しています。ほとんどのFTC症例は進行が遅く、手術と放射性ヨード（RAI）療法によって初期治療が可能であるが、患者の一部はRAI不応性疾患を発症し、全身的な薬理学的介入が必要となります。この臨床的ギャップは、無増悪生存期間を改善し、転移リスクを低減し、治療抵抗性病態に対処することを目的とした標的治療の技術革新を促しています。

治療の焦点は、一般的な化学療法剤から、FTCの進行に関連する血管新生、チロシンキナーゼ活性、その他の発がん経路を阻害する分子標的薬へと移行しつつあります。RAS、PAX8/PPARγ再配列、PI3K/ACTシグナル伝達など、FTCに関与する遺伝子変異や分子経路の理解が深まるにつれ、個別化医療のアプローチが薬剤開発パイプラインを再構築しつつあります。バイオマーカー主導型治療を支持するエビデンスの増加により、進行性または転移性の濾胞性甲状腺がん患者に対して、より正確で忍容性の高い治療が可能となっています。

どの薬剤クラス別および薬剤機序が現在および新たな治療法をリードしているか？

チロシンキナーゼ阻害薬（TKI）は、特にRAIに反応しない症例において、進行性FTCに対する薬物療法の要となっています。承認されたマルチキナーゼ阻害剤であるlikelenvatinibとsorafenibは、当初はより広範な甲状腺悪性腫瘍を対象として開発されたが、VEGFR、FGFR、RET、PDGFR経路を標的とすることにより、疾患の進行を遅らせる臨床的有効性を示しました。これらの薬剤は、外科手術の選択肢がもはや実行不可能な局所進行性または転移性の患者にしばしば使用されます。

新たな治療法としては、RET特異的阻害剤（例えば、セルパーカチニブ）や、重複する遺伝子変化を有する患者に対するBRAF/MEK阻害剤など、より選択的な作用機序が模索されています。免疫療法は、FTCに対してはまだ初期段階の研究であるが、RAI不応の環境で抗腫瘍免疫応答を刺激する可能性が評価されています。さらに、MEK阻害剤のような再分化剤が難治性腫瘍のヨード取り込みを回復させ、RAI療法に再感作させる可能性が検討されています。これらの次世代薬剤は、個別化治療や併用療法への戦略的進化を意味します。

臨床実践と患者層は市場の需要にどのような影響を与えているか？

FTCを含む甲状腺がんの罹患率は、画像診断の向上、サーベイランスの強化、認知度の向上により、世界的に上昇しています。FTCは中高年に多く発症し、限局性であれば予後は一般に良好ですが、末期症例では長期の全身管理が必要となります。生存率が向上するにつれて、持続的な薬物療法を含む慢性期医療モデルがより適切なものとなり、忍容性が高く効果的な薬剤に対する長期的な市場需要が高まっています。

臨床現場では、特に進行期の患者を対象に、診断時や再発時にゲノム・プロファイリングを行い、治療法の選択に役立てるケースが増えています。このような精密さ主導のアプローチは、標的治療の早期開始を促し、治療成績を改善し、コンパニオン診断薬の需要を促進します。管理可能な副作用プロファイルを持つ経口、外来投与療法に対する患者の期待は、TKIや他の新規薬剤の取り込みに影響を与えています。特に新興国市場の医療制度は、償還の枠組みや臨床ガイドラインに支えられて、これらの治療法を甲状腺がん管理プロトコールに組み入れつつあります。

濾胞性甲状腺がん治療薬市場の成長を促進する中核要因は何か？

濾胞性甲状腺がん治療薬市場の成長は、臨床ニーズ、科学的進歩、治療基準の進化に関連するいくつかの重要な要因によってもたらされます。その最たるものが、RAI不応性FTCにおける有効な治療オプションに対するアンメットニーズです。分化型甲状腺がんにおけるマルチキナーゼ阻害剤の成功は、血管新生と成長因子経路阻害の治療可能性を検証し、さらなる薬剤開発のための強力な基盤を作り上げました。

分子腫瘍学への継続的な投資は、希少疾病用医薬品としての適応や迅速承認に対する規制当局の支援と相まって、新規治療薬の導入を加速させています。分子診断学と標的治療パラダイムの拡大も、高度な薬理学的介入が有効な可能性のあるFTC患者の同定増加に寄与しています。さらに、がんに対する意識の高まり、新興国におけるヘルスケア・アクセスの改善、個別化医療の役割の高まりが、より広範な採用と商業的成長に寄与しています。これらの要因が相まって、濾胞性甲状腺がん治療薬市場は今後10年間にわたって継続的な革新と拡大が見込まれます。

セグメント

タイプ（乳頭がんタイプ、濾胞がんタイプ、その他のタイプ）;エンドユーザー（病院＆クリニックエンドユーザー、外来手術センターエンドユーザー、その他のエンドユーザー）

調査対象企業の例（注目の41社）

  • AffyImmune Therapeutics Inc
  • Alphamab Oncology
  • AstraZeneca Plc
  • Bayer AG
  • BeOne Medicines（formerly BeiGene）
  • Bio-Thera Solutions Ltd
  • Bristol-Myers Squibb Co
  • Celgene Corporation
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Jiangsu Hengrui Medicine Co Ltd
  • Loxo Oncology Inc
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc
  • Recordati SpA
  • Salubris Biotherapeutics Inc
  • Sanofi S.A.
  • Suzhou SmartNuclide Biopharmaceutical Co Ltd
  • Suzhou Zelgen Biopharmaceutical Co Ltd
  • Teva Pharmaceutical Industries Ltd

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP36925

Global Follicular Thyroid Cancer Drugs Market to Reach US$908.5 Million by 2030

The global market for Follicular Thyroid Cancer Drugs estimated at US$715.3 Million in the year 2024, is expected to reach US$908.5 Million by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Papillary Carcinoma Type, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$515.5 Million by the end of the analysis period. Growth in the Follicular Carcinoma Type segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$194.9 Million While China is Forecast to Grow at 7.4% CAGR

The Follicular Thyroid Cancer Drugs market in the U.S. is estimated at US$194.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$184.6 Million by the year 2030 trailing a CAGR of 7.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Global Follicular Thyroid Cancer Drugs Market - Key Trends & Drivers Summarized

Why Is the Therapeutic Landscape for Follicular Thyroid Cancer Evolving Rapidly?

Follicular thyroid cancer (FTC), the second most common type of differentiated thyroid cancer after papillary thyroid carcinoma, presents unique therapeutic challenges and opportunities. While most FTC cases are slow-growing and initially treatable via surgery and radioactive iodine (RAI) therapy, a subset of patients develops RAI-refractory disease that necessitates systemic pharmacological intervention. This clinical gap is driving innovation in targeted therapies aimed at improving progression-free survival, reducing metastasis risk, and addressing treatment-resistant disease states.

The therapeutic focus is shifting from generalized chemotherapeutic agents to molecularly targeted drugs that inhibit angiogenesis, tyrosine kinase activity, and other oncogenic pathways associated with FTC progression. As understanding of the genetic mutations and molecular pathways involved in FTC-such as RAS, PAX8/PPARγ rearrangements, and PI3K/AKT signaling-deepens, personalized medicine approaches are reshaping the drug development pipeline. The growing body of evidence supporting biomarker-driven therapy is enabling more precise and tolerable treatments for patients with advanced or metastatic follicular thyroid cancer.

Which Drug Classes and Mechanisms Are Leading Current and Emerging Therapies?

Tyrosine kinase inhibitors (TKIs) have become the cornerstone of drug therapy for advanced FTC, particularly in cases unresponsive to RAI. Approved multi-kinase inhibitors like lenvatinib and sorafenib-initially developed for broader thyroid malignancies-have demonstrated clinical efficacy in slowing disease progression by targeting VEGFR, FGFR, RET, and PDGFR pathways. These agents are often used in patients with locally advanced or metastatic disease where surgical options are no longer viable.

Emerging therapies are exploring more selective mechanisms of action, including RET-specific inhibitors (e.g., selpercatinib) and BRAF/MEK inhibitors for patients with overlapping genetic alterations. Immunotherapies, though still in early-phase investigation for FTC, are being evaluated for their potential to stimulate anti-tumor immune responses in RAI-refractory settings. Additionally, redifferentiation agents-such as MEK inhibitors-are being explored to restore iodine uptake in refractory tumors, potentially resensitizing them to RAI therapy. These next-generation drugs represent a strategic evolution toward personalized and combination-based treatment modalities.

How Are Clinical Practices and Patient Demographics Influencing Market Demand?

The incidence of thyroid cancer, including FTC, is rising globally-driven by better diagnostic imaging, increased surveillance, and awareness. FTC disproportionately affects middle-aged and older adults, and while prognosis is generally favorable for localized disease, late-stage cases require long-term systemic management. As survival improves, chronic care models involving sustained drug therapy become more relevant, boosting long-term market demand for well-tolerated and effective agents.

Clinical practices are increasingly adopting genomic profiling at the time of diagnosis or relapse to guide therapy selection, particularly for advanced-stage patients. This precision-driven approach encourages early initiation of targeted therapies, improving treatment outcomes and fostering demand for companion diagnostics. Patient expectations for oral, outpatient-administered therapies with manageable side effect profiles are influencing the uptake of TKIs and other novel agents. Health systems, especially in developed markets, are incorporating these therapies into thyroid cancer management protocols, supported by reimbursement frameworks and clinical guidelines.

What Are the Core Factors Driving Growth in the Follicular Thyroid Cancer Drugs Market?

The growth in the follicular thyroid cancer drugs market is driven by several key factors linked to clinical need, scientific advancement, and evolving treatment standards. Chief among these is the unmet demand for effective treatment options in RAI-refractory FTC, where survival outcomes remain suboptimal. The success of multi-kinase inhibitors in differentiated thyroid cancers has validated the therapeutic potential of angiogenesis and growth factor pathway inhibition, creating a strong foundation for further drug development.

Continued investments in molecular oncology, coupled with regulatory support for orphan indications and fast-track drug approvals, are accelerating the introduction of novel therapies. The expansion of molecular diagnostics and targeted treatment paradigms is also contributing to increased identification of FTC patients who may benefit from advanced pharmacological interventions. Furthermore, rising cancer awareness, improving healthcare access in emerging economies, and the growing role of personalized medicine are contributing to broader adoption and commercial growth. Together, these forces position the follicular thyroid cancer drugs market for continued innovation and expansion over the next decade.

SCOPE OF STUDY:

The report analyzes the Follicular Thyroid Cancer Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Papillary Carcinoma Type, Follicular Carcinoma Type, Other Types); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • AffyImmune Therapeutics Inc
  • Alphamab Oncology
  • AstraZeneca Plc
  • Bayer AG
  • BeOne Medicines (formerly BeiGene)
  • Bio-Thera Solutions Ltd
  • Bristol-Myers Squibb Co
  • Celgene Corporation
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Jiangsu Hengrui Medicine Co Ltd
  • Loxo Oncology Inc
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc
  • Recordati SpA
  • Salubris Biotherapeutics Inc
  • Sanofi S.A.
  • Suzhou SmartNuclide Biopharmaceutical Co Ltd
  • Suzhou Zelgen Biopharmaceutical Co Ltd
  • Teva Pharmaceutical Industries Ltd

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Follicular Thyroid Cancer Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advancements in Molecular Diagnostics Drive Early Detection and Targeted Therapies
    • Rising Prevalence of Differentiated Thyroid Cancer Spurs Drug Development Activity
    • Breakthroughs in Tyrosine Kinase Inhibitors Strengthen Business Case for Targeted Agents
    • FDA Approvals of Orphan Drugs Accelerate Commercialization of Novel Therapies
    • Clinical Trials Exploring Combination Therapies Propel Market Expansion
    • Increasing Emphasis on Personalized Medicine Enhances Adoption of Genetic Testing Tools
    • Radiotherapeutic Innovations Sustain Demand for Radioiodine-Based Therapies
    • Improvements in Drug Delivery Mechanisms Expand Patient Compliance and Efficacy
    • Advancements in Liquid Biopsy Enable Real-Time Monitoring of Tumor Markers
    • Surge in Oncology-Focused Biotech Funding Fuels R&D in Thyroid Cancer Therapeutics
    • Growing Use of Companion Diagnostics Drives Precision Drug-Patient Matching
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Follicular Thyroid Cancer Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Follicular Thyroid Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Follicular Thyroid Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Papillary Carcinoma Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Papillary Carcinoma Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Papillary Carcinoma Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Follicular Carcinoma Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Follicular Carcinoma Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Follicular Carcinoma Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Follicular Thyroid Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Follicular Thyroid Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Follicular Thyroid Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Follicular Thyroid Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Follicular Thyroid Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Follicular Thyroid Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Follicular Thyroid Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Follicular Thyroid Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Follicular Thyroid Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Follicular Thyroid Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Follicular Thyroid Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Follicular Thyroid Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Follicular Thyroid Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Follicular Thyroid Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Follicular Thyroid Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Follicular Thyroid Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Follicular Thyroid Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Follicular Thyroid Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Follicular Thyroid Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Follicular Thyroid Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Follicular Thyroid Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Follicular Thyroid Cancer Drugs by Type - Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Follicular Thyroid Cancer Drugs by Type - Percentage Breakdown of Value Sales for Papillary Carcinoma Type, Follicular Carcinoma Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Follicular Thyroid Cancer Drugs by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Follicular Thyroid Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION